{
    "medicine_id": "1abdcfcebc27a88c82ec31bb7d4a76e57179b660",
    "platform_id": "DB04858",
    "metadata": {
        "name": "Multaq 400 mg Tablet film coated",
        "composition": "400 mg Tirapazamine",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of head and neck cancer",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Tirapazamine is a anticancer drug that is inactive in normal tissues that are well oxygenated but becomes active at the low oxygen levels found in solid tumors As a result the drug kills these poorly oxygenated or hypoxic cells while limiting toxicity in normal tissue Tirapazamine may prove highly effective when used in combination with standard anticancer therapy as these hypoxic cells are characteristically resistant to radiation and common anticancer agents",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tirapazamine"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tirapazamine"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tirapazamine"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Tirapazamine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}